Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
San Raffaele University
Eikon Therapeutics
VA Office of Research and Development
Radiopharm Theranostics, Ltd
Replimune Inc.
Fudan University
St. Jude Children's Research Hospital
Novartis
University of Cincinnati
GlaxoSmithKline
Women's Hospital School Of Medicine Zhejiang University
UNICANCER
ImmunityBio, Inc.
Shanghai Zhongshan Hospital
Sun Yat-sen University
7 Hills Pharma, LLC
University of Pittsburgh
AIO-Studien-gGmbH
GERCOR - Multidisciplinary Oncology Cooperative Group
Sanford Health
M.D. Anderson Cancer Center
WellSpan Health
Sun Yat-sen University
Incyte Corporation
Ohio State University Comprehensive Cancer Center
University of Pittsburgh
Queensland Centre for Gynaecological Cancer
San Raffaele University
Molecular Templates, Inc.
Massachusetts General Hospital
Peking University People's Hospital
West China Hospital
The Hospital for Sick Children
Henan Cancer Hospital
Institut Bergonié
Third Affiliated Hospital, Sun Yat-Sen University
National Institutes of Health Clinical Center (CC)
University of Colorado, Denver
Incyte Corporation
National Cancer Institute (NCI)
Sun Yat-sen University